Skip to main content
. 2022 Dec 1;28(12):2633–2645. doi: 10.1038/s41591-022-02059-9

Fig. 5. LNA043 is safe in the FIH study.

Fig. 5

a, Table summarizing the adverse events (AEs) that occurred at least twice, reported per treatment arm and not showing clear trends in safety. b, Table reporting all of the serious adverse events (SAEs), also not showing safety trends, and with none of them suspected to be related to LNA043. Cohorts 1 and 4–6 are not included as there were no SAEs in these cohorts; however, the final column includes these participants in the total.